TY - JOUR
T1 - The potential of metabolomics in the diagnosis of thyroid cancer
AU - Coelho, Margarida
AU - Raposo, Luis
AU - Goodfellow, Brian J.
AU - Atzori, Luigi
AU - Jones, John
AU - Manadas, Bruno
N1 - Funding Information:
This work was supported by the European Regional Development Fund (ERDF) through the COMPETE 2020—Operational Programme for Competitiveness and Internationalisation and Portuguese national funds via FCT—Fundação para a Ciência e a Tecnologia, I.P., under projects: POCI-01-0145-FEDER-007440 (Ref. UIDB/04539/2020), POCI-01-0145-FEDER-016428 (Ref. SAICTPAC/0010/2015), POCI-01-0145-FEDER-029311 (Ref. PTDC/BTM-TEC/29311/2017), POCI-01-0145-FEDER-30943 (Ref. PTDC/MEC-PSQ/30943/2017) and PTDC/MED-NEU/27946/2017; and by The National Mass Spectrometry Network (RNEM) under the contract POCI-01-0145-FEDER-402-022125 (Ref. ROTEIRO/0028/2013). MC was supported by PhD fellowship PD/BD/135178/2017, co-financed by the European Social Fund (ESF) through the POCH (Programa Operacional do Capital Humano) and national funds via FCT.
Publisher Copyright:
© 2020 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2020/8
Y1 - 2020/8
N2 - Thyroid cancer is the most common endocrine system malignancy. However, there is still a lack of reliable and specific markers for the detection and staging of this disease. Fine needle aspiration biopsy is the current gold standard for diagnosis of thyroid cancer, but drawbacks to this technique include indeterminate results or an inability to discriminate different carcinomas, thereby requiring additional surgical procedures to obtain a final diagnosis. It is, therefore, necessary to seek more reliable markers to complement and improve current methods. “Omics” approaches have gained much attention in the last decade in the field of biomarker discovery for diagnostic and prognostic characterisation of various pathophysiological conditions. Metabolomics, in particular, has the potential to identify molecular markers of thyroid cancer and identify novel metabolic profiles of the disease, which can, in turn, help in the classification of pathological conditions and lead to a more personalised therapy, assisting in the diagnosis and in the prediction of cancer behaviour. This review considers the current results in thyroid cancer biomarker research with a focus on metabolomics.
AB - Thyroid cancer is the most common endocrine system malignancy. However, there is still a lack of reliable and specific markers for the detection and staging of this disease. Fine needle aspiration biopsy is the current gold standard for diagnosis of thyroid cancer, but drawbacks to this technique include indeterminate results or an inability to discriminate different carcinomas, thereby requiring additional surgical procedures to obtain a final diagnosis. It is, therefore, necessary to seek more reliable markers to complement and improve current methods. “Omics” approaches have gained much attention in the last decade in the field of biomarker discovery for diagnostic and prognostic characterisation of various pathophysiological conditions. Metabolomics, in particular, has the potential to identify molecular markers of thyroid cancer and identify novel metabolic profiles of the disease, which can, in turn, help in the classification of pathological conditions and lead to a more personalised therapy, assisting in the diagnosis and in the prediction of cancer behaviour. This review considers the current results in thyroid cancer biomarker research with a focus on metabolomics.
KW - Biomarker
KW - Diagnosis
KW - Metabolite
KW - Metabolomics
KW - Thyroid cancer
UR - http://www.scopus.com/inward/record.url?scp=85088578478&partnerID=8YFLogxK
U2 - 10.3390/ijms21155272
DO - 10.3390/ijms21155272
M3 - Review article
C2 - 32722293
AN - SCOPUS:85088578478
SN - 1661-6596
VL - 21
SP - 1
EP - 22
JO - International Journal of Molecular Sciences
JF - International Journal of Molecular Sciences
IS - 15
M1 - 5272
ER -